A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

References

• Cudkowicz ME, van den Berg LH, Shefner J, Mitsumoto H, Mora J, Ludolph A, et al. Dexpramipexole in amyotrophic lateral sclerosis: results of the randomized, double-blind, placebo-controlled phase III EMPOWER trial. Lancet Neurol. 2013;12:1059–67.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652–6.
   PubMed Web of Science ®Google Scholar
• Rilutek® (riluzole) Tablets Description: http://products.sanofi.us/rilutek/rilutek.pdf
   Google Scholar
• Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population based study. Neurology. 2003;60:813–9.
   PubMed Web of Science ®Google Scholar
• Scotton WJ, Scott KM, Moore DH, Almedom L, Wijesekera LC, Jannsen A, et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:502–8.
   PubMed Web of Science ®Google Scholar
• Ratti E, Berry JD, Atassi N, Shui A, Hayden D, Schoenfeld D, et al. Predictors of outcomes in amyotrophic lateral sclerosis. Neurology. 2014;82:P2.076.
   Google Scholar
• Turner MR, Kiernan MC, Leigh N, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8: 94–109.
   PubMed Web of Science ®Google Scholar
• Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler. 2005;6:37–44.
   PubMed Web of Science ®Google Scholar
• Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12: 310–22.
   PubMed Web of Science ®Google Scholar
• Ravits J, Appel SH, Baloh R, Barohn R, Brooks BR, Elman L, et al. Deciperhing amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(Suppl 1):5–18.
   PubMed Web of Science ®Google Scholar
• Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162–8.
   PubMed Web of Science ®Google Scholar
• Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18: 1341–54.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012;13:110–8.
   PubMed Web of Science ®Google Scholar
• Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14:248–64.
   PubMed Web of Science ®Google Scholar
• Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, et al. Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(Suppl 1):53–61.
   PubMedGoogle Scholar
• Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF 1 is not beneficial in two-year ALS trial. Neurology. 2008;71:1770–5.
   PubMed Web of Science ®Google Scholar
• Shefner JM. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2008;19:495–508.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Katz J, Moore DH, O’Neill G, Glass JD, Mitsumoto H, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010; 11:259–65.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Gordon P, Kaufmann P, Gooch CL, Przedborski S, Rowland LP. Randomized control trials in ALS: lessons learned. Amyotroph Lateral Scler. 2004; 5 (Suppl 1):8–13.
   Google Scholar
• U.S. Department of Health and Human Services. Guidance for Industry, ‘Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products’ (Draft Guidance): http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/GuidaGuid/UCM332181.pdf
   Google Scholar
• UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, et alLithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase III multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339–45.
   PubMed Web of Science ®Google Scholar
• Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al; TCH346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;69:776–84.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol. 2007;6:1045–53.
   PubMed Web of Science ®Google Scholar
• Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, et al; Northeast ALS Consortium. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013;8:e61177.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Shefner J, NEALS Consortium. Stage III clinical trial of ceftriaxone in subjects with ALS. Neurology. 2013;80:S36.001.
   Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. SLAP registry. Riluzole and amyotrophic lateral sclerosis survival: a population based study in southern Italy. Eur J Neurol. 2007;14: 262–8.
   PubMed Web of Science ®Google Scholar
• Meininger V, Bensimon G, Bradley WR, Brooks B, Douillet P, Eisen AA, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler. 2004;5:107–17.
   PubMed Web of Science ®Google Scholar
• Meininger V, Asselain B, Guillet P, Leigh PN, Ludolph A, Lacomblez L, et al; Pentoxifylline European Group. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology. 2006;66: 88–92.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al; CONFIRM Study Investigators. Placebo-controlled phase III study of oral BG-12 or glatiramer in multiple sclerosis. NEJM. 2012;367:1087–97.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Havrdova E, Radue EW, O’Connor P, Zhang-Auberson L, Agoropoulou C, et al; FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomized, placebo- controlled FREEDOMS study. Lancet Neurol. 2012;11: 420–8.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, et al; CLARITY study group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post hoc and subgroup analysis. Lancet Neurol. 2011;10:329–37.
   PubMed Web of Science ®Google Scholar
• Sun X, Briel M, Busse JW, Akl EA, You JJ, Mejza F, et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials. 2009;10: 101.
   PubMedGoogle Scholar
• Lagakos SW. The challenge of subgroup analyses: reporting without distorting. NEJM. 2006;354:1667–9.
   PubMed Web of Science ®Google Scholar
• Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. NEJM. 2007;357:2189–94.
   PubMed Web of Science ®Google Scholar
• Rothwell PM. Subgroup analysis in randomized controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–86.
   PubMed Web of Science ®Google Scholar